Shield Therapeutics receives CHMP positive opinion for Feraccru® (Ferric Maltol) for the treatment of Iron Deficiency in adults

23 Feb 2018

Shield Therapeutics announced to the market today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorisation approval of Feraccru® (Ferric Maltol) to be extended to include treatment of all adults with iron deficiency (ID) with or without anaemia.

Please see the press release for further information.

CHMP POS opinion FINAL

Back to news